<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170010</url>
  </required_header>
  <id_info>
    <org_study_id>Weight loss gut peptide study</org_study_id>
    <nct_id>NCT04170010</nct_id>
  </id_info>
  <brief_title>Long Term Effects of Weight Loss on Post-prandial Gut Hormone Responses and Meal Induced Thermogenesis</brief_title>
  <official_title>Postprandial Gut Hormone Responses and Meal-induced Thermogenesis After Non-surgical Long-term Weight Loss; Comparison With Surgically Treated Obese Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine post-prandial gut-hormone secretion, meal-induced thermogenesis, fasting&#xD;
      plasma metabolomic/lipidomic and cardiovascular indices among surgically managed obese&#xD;
      individuals in the long term compared to conservatively managed obese patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a protocol for the study of post-prandial gut peptide response and meal-induced&#xD;
      thermogenesis in a group of 15 conservatively managed (through diet and exercise) morbidly&#xD;
      obese individuals. During two separate visits in the study site, anthropometric and&#xD;
      bioelectric impendence data will be collected, resting metabolic rate will be measured, and&#xD;
      the patients will undergo a panel of cardiovascular examinations (heart rate variability,&#xD;
      baroreflex sensitivity, heart ultrasound). On a separate occasion, they will consume a&#xD;
      standardized test mixed meal and complete visual analog scales for the subjective assessment&#xD;
      of hunger and fullness every 30 minutes for 3 hours. At the same time points, blood samples&#xD;
      will be collected for the consequent measurement of glucose, insulin, lipids, and&#xD;
      gastrointestinal hormones. Additionally, immediately before and at 60', 120', 180' after the&#xD;
      start of the consumption of the test meal, the resting metabolic rate of each participant&#xD;
      will be assessed through indirect calorimetry, to quantify meal-induced thermogenesis. The&#xD;
      observed induction of satiety and suppression of hunger, post prandial gut-peptide&#xD;
      mobilization and change in metabolic rate will be compared to those of participants of trial&#xD;
      no NCT03851874 (Morbidly obese patients that have undergone either Roux en Y gastric bypass&#xD;
      or sleeve gastrectomy and participated in trial NCT03851874). Participants in the&#xD;
      aforementioned cohort have been already followed-up during the first postoperative year and&#xD;
      will attend the study site for another follow-up visit approximately 10 years&#xD;
      postoperatively, whereby the same diagnostic evaluation described above will take place. Data&#xD;
      analysis will take place within the bariatric cohort (longitudinal analysis of the effects of&#xD;
      surgery and surgery types on anthropometric parameters, fasting and postprandial glycemia and&#xD;
      lipemia, fasting NMR-Metabolomic/Lipidomic profiles, Indices of insulin resistance,&#xD;
      echocardiography, energy expenditure) as well as between the two groups in a cross-sectional&#xD;
      manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial Gut peptide (ghrelin, Gastric Inhibitory Peptide, Secretin, Peptide Tyrosine-Tyrosine - , Glucagon-like peptide - 1, Oxyntomodulin, Glicentin) responses</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial response for the aforementioned gut hormones</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weight, fat mass and lean body mass</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in weight (percentage of weight following each intervention)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glycemia</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in postprandial glycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulinemia</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial response for insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial triglyceridemia</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial response for triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin resistance</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in Insulin resistance indices (HOMA-R, MMTT-derived Matsuda index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum metabolomic and lipidomic parameters</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in levels of lipoprotein clusters, branched-chain amino-acids, LDL/HDL-Subtypes, Trimethylamine N-oxide assessed by NMR spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting metabolic rate following meal ingestion</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial thermogenesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum adipokines</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change of fasting leptin, adiponektin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma Activins and follistatins</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in fasting plasma Activin A, B, AB, follistatin and follistatin-like 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial Visual Analog Scale scores for hunger and satiety</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in postprandial areas under the curve of subjective hunger and satiety expressed in Visual Analog Scales</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in baroreflex sensitivity</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Changes in baroreflex sensitivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in heart rate variability</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Changes in heart rate variability</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in aortic distensibility</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Aortic distensibility will be evaluated by calculating the systolic and diastolic aortic diameter through M-mode echocardiography, 3 cm above the aortic valve, using the formula described in reference no 4 (PMID: 2282929)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiographic cardiac phenotype</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in echocardiographic cardiac structural indices and measures of systolic and diastolic function</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Conservatively managed group</arm_group_label>
    <description>Individuals with conservatively managed obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgically managed group</arm_group_label>
    <description>Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intervention group: participants of NCT03851874 trial Control group: conservatively&#xD;
        (non-surgically, non-pharmaceutically) managed obese individuals among ambulatory patients&#xD;
        of the obesity outpatient clinic of the 1st Department of Propaedeutic Internal Medicine&#xD;
        (&quot;Laiko&quot; General Hospital)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For the conservatively managed cohort:&#xD;
&#xD;
               1. Morbid obesity based on BMI &gt; 40kg/m2, managed exclusively with conservative&#xD;
                  measures (hypocaloric diet and/or increased physical activity and/or behavioral&#xD;
                  therapy)&#xD;
&#xD;
               2. Age between 18 and 65 years&#xD;
&#xD;
          -  For the bariatric cohort: Participation in NCT03851874 trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious and life threatening comorbidities (renal, cardiac, liver failure, or&#xD;
             malignancy)&#xD;
&#xD;
          2. Alcohol or other substance abuse&#xD;
&#xD;
          3. Use of licenced or off-label weight loss medications during the past 6 months&#xD;
&#xD;
          4. Concurrent psychiatric illness&#xD;
&#xD;
          5. Known history of diabetes mellitus (remitted cases excluded)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Propaedeutic Medicine, NKUA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <phone>+302132061248</phone>
    <email>akokkinos@med.uoa.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Clinical Research Laboratory, 1st Department of Propaedeutic Internal Medicine</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kokkinos, MD, PhD</last_name>
      <phone>+302132061248</phone>
      <email>akokkinos@med.uoa.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Pilitsi E, Upadhyay J, Alexandrou A, Mantzoros CS. Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. Metabolism. 2019 Dec;101:153997. doi: 10.1016/j.metabol.2019.153997. Epub 2019 Oct 28.</citation>
    <PMID>31672446</PMID>
  </reference>
  <reference>
    <citation>Liaskos C, Koliaki C, Alexiadou K, Argyrakopoulou G, Tentolouris N, Diamantis T, Alexandrou A, Katsilambros N, Kokkinos A. Roux-en-Y Gastric Bypass Is More Effective than Sleeve Gastrectomy in Improving Postprandial Glycaemia and Lipaemia in Non-diabetic Morbidly Obese Patients: a Short-term Follow-up Analysis. Obes Surg. 2018 Dec;28(12):3997-4005. doi: 10.1007/s11695-018-3454-y.</citation>
    <PMID>30112599</PMID>
  </reference>
  <reference>
    <citation>Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014 Feb;24(2):241-52. doi: 10.1007/s11695-013-1066-0.</citation>
    <PMID>23996294</PMID>
  </reference>
  <reference>
    <citation>Stefanadis C, Stratos C, Boudoulas H, Kourouklis C, Toutouzas P. Distensibility of the ascending aorta: comparison of invasive and non-invasive techniques in healthy men and in men with coronary artery disease. Eur Heart J. 1990 Nov;11(11):990-6.</citation>
    <PMID>2282929</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Alexandros Kokkinos</investigator_full_name>
    <investigator_title>Associate Professor in Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Weight loss</keyword>
  <keyword>Gut peptides</keyword>
  <keyword>Meal-induced thermogenesis</keyword>
  <keyword>Glycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

